文献速递中药与中成药合理使用中医内科

基于变量投影重要性分析喜炎平注射液严重不良反应的风险因素

Variable importance for projection (VIP) scores for analyzing the contribution of risk factors in severe adverse events to Xiyanping injection.
PubMed 文献 · Chin Med · 2023-02-13

研究提取2004—2017年国家药品不良反应监测系统中喜炎平注射液相关不良反应,按年龄和12种药物联用分析变量投影重要性(VIP)评分与相关系数。共纳入21,714例不良反应(一般20,660例,严重1,054例)。年龄是影响不良反应严重程度的关键因素,且不同年龄段影响方向不同;单独使用喜炎平倾向于发生一般不良反应。

要点

  • 年龄是喜炎平注射液相关不良反应严重程度的关键影响因素。
  • 0—6岁患者倾向于发生一般不良反应,>41岁患者倾向于发生严重不良反应。
  • 单独使用喜炎平倾向于一般不良反应,应严格执行用药间隔和冲管等规范操作。

核心结论

  • VIP法可有效分析影响喜炎平注射液不良反应严重程度的风险因素。
  • 年龄是影响不良反应严重程度的关键因素,且不同年龄段影响方向不同。
  • 单独使用喜炎平是安全的,严格实施用药间隔和冲管等标准化操作可避免非预期不良反应。

研究设计与样本

  • 提取2004—2017年中国国家药品不良反应监测信息系统中喜炎平注射液相关不良反应,分为一般和严重两类。
  • 按年龄和12种药物联用(包括利巴韦林、头孢曲松、青霉素钠、盐酸氨溴索等)分析VIP评分和相关系数。
  • 共纳入21,714例喜炎平联用相关不良反应(一般20,660例;严重1,054例)。

主要发现

  • 单独使用喜炎平倾向于产生一般不良反应(All VIP=3.124; 1.329; 1.857; 2.169; 2.400,Coeff<0)。
  • 全部数据集中,0—6岁患者倾向于一般不良反应(VIP=2.425,Coeff<0),>41岁患者倾向于严重不良反应(VIP=1.180; 2.323,Coeff>0)。
  • 0—40岁患者中,喜炎平-利巴韦林联用对不良反应严重程度影响较大(VIP=1.158; 1.360; 1.147,Coeff>0)。
  • 7—17岁患者中,喜炎平-阿奇霉素联用倾向于一般不良反应(VIP=1.502,Coeff<0)。
  • >65岁人群中,喜炎平-盐酸氨溴索联用倾向于严重不良反应(VIP=1.232,Coeff>0)。

临床怎么用

  • 临床应关注不同年龄段的代谢特征,尤其是>41岁和>65岁患者使用喜炎平时的严重不良反应风险。
  • 单独使用喜炎平并严格执行用药间隔和冲管等规范操作,可避免非预期不良反应。
  • 对0—40岁患者联用利巴韦林、7—17岁患者联用阿奇霉素、>65岁患者联用盐酸氨溴索时,需注意不良反应严重程度的影响方向。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Age and herb-drug combination are risk factors for the severity of Xiyanping injection (XYP) associated adverse events (AEs). OBJECTIVE: To analyze risk factors contributing to the severity of XYP's AEs using a variable importance for projection (VIP) method. METHODS: AEs related to the use of XYP were extracted from the China National Adverse Drug Reaction Monitoring Information System (2004-2017) and classified as general or severe. Data were analyzed with respect to age and 12 herb-drug combinations, including ribavirin (RB), ceftriaxone, penicillin sodium, ambroxol hydrochloride (AH), clindamycin, cefoxitin sodium, azithromycin (AZM), ceftazidime, amoxicillin sodium/potassium clavulanate, levofloxacin hydrochloride, sodium cefazolin pentahydrate, and acyclovir according to VIP scores and correlation coefficient (Coeff). RESULTS: A total of 21,714 AEs (general 20,660; severe 1054) related to XYP combinations were included. Using XYP alone tended to produce general AEs (All VIP = 3.124; 1.329; 1.857; 2.169; 2.400, Coeff < 0). For all set, 0-6 years old patients tend to have general AEs (VIP = 2.425, Coeff < 0), while those > 41 years old patients tend to have severe AEs (VIP = 1.180; 2.323, Coeff > 0). For 0-40 years old patients, XYP-RB combination had a greater impact on the severity of AEs (VIP = 1.158; 1.360; 1.147, Coeff > 0). For 7-17 years old patients, XYP-AZM combination tended to produce general AEs (VIP = 1.502, Coeff < 0). In individuals > 65 years old, XYP-AH combination tended to result in severe AEs (VIP = 1.232, Coeff > 0). CONCLUSIONS: VIP method was expected to effectively analyze risk factors in affecting the severity of AEs and control AEs more effectively. Age is the key factor contributing to the severity of AEs, and there are different influence directions. It is recommended that clinicians pay closer attention to the metabolic characteristics of different age groups. It is safe to use XYP alone and strictly implementing standardized operations such as medication interval and flushing will avoid undesired AEs.

来源:Chin Med,查看原文。版权归原作者所有。

引用

  1. Zheng R, Chen Z, Guan Z, et al. Variable importance for projection (VIP) scores for analyzing the contribution of risk factors in severe adverse events to Xiyanping injection. Chin Med. 2023. PMID: 36782216. doi:10.1186/s13020-023-00718-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。